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Objective To compare a new loading dose regimen for intravenous ritodrine administration in
preterm labour with the conventional dose regimen.
Design Multicentre randomised trial using numbered opaque sealed envelopes.
Setting Five teaching hospitals in the Netherlands.
Participants Women (n =  203) in preterm labour at less than 34 weeks of gestation.
Interventions Women received either a loading dose ritodrine infusion followed, as soon as
tocolysis was reached, by a decrease in infusion rate or the conventional schedule of increasing 
doses until uterine quiescence was achieved.
Results Frequency of successful tocolysis (71 %) and duration of treatment (55 h) were similar in
both groups, but the loading dose schedule was better tolerated with fewer adverse events. Also 
the number of dose adjustments was smaller than in the incremental dose group (P <  0-001). 
Overall, the differences between the two regimens were unexpectedly small.
Conclusions Despite the small differences, the loading model is easier to apply, requires fewer dose
adjustments, is better tolerated with less side effects, and reduces the likelihood of clinical error.
INTRODUCTION
Classically, ritodrine, the most commonly used 
betamimetic agent for treatment of preterm labour, 
is administered intravenously in stepwise incre­
mental doses until uterine quiescence is achieved 
or side effects preclude further increases1,2. This 
approach results in a gradual increase in plasma 
ritodrine concentrations that continues even after
has r c i '1 *
Bee total
dose and dose changes'-,r’ we designed a loading 
dose schedule with two main characteristics”. It 
avoids doses in excess of those needed to achieve 
and maintain uterine quiescence ind r
only one or two adjustments of the infusion rate to 
reach an effective minimal infusion rate”.
We now report on a randomised
study in which the new loading dose regimen was 
compared with the conventional system of rito-
rnm 4NW
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drine administration for treatment of preterm 
labour.
METHODS
Five teaching hospitals participated in this 4 year
(shorter at some hospitals) after ethical 
approval of a protocol that consisted of two parts. 
The first part, which is reported here, consisted of 
a comparison between loading
dose (LD) and a conventional incremental dose 
(ID) regimen for intravenous ritodrine adminis-
tration ln labour. The ; part.
which is reported separately, was a double-blind, 
placebo-controlled evaluation of sustained release 
ritodrine capsules for maintaining uterine relax­
ation in those women whose preterm labour had 
been arrested by these treatments (Fig. I)7. 
Irrespective of whether they had received the LD 
or the ID schedule, women participating in the 
second par t had an equal chance of being allocated 
blindly to placebo or sustained release ritodrine 
capsules. This implies that the influence of main-
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Women in preterm labour allocated to receive ritodrine by
I
Loading dose regimen Incremental dose regimen |
I i i 1
Failure Success 1 Success Failure
I 1 I
Candidates for maintenance trial I
I i  i t ^
Non-participants | Pla | Rit | Rit Pla | Non-participants
i 1 | I * 1
Outcome loading dose | Outcome incremental dose
Table 1. Regimen used for ritodrine administration starting 
with a loading dose infusion rate of 200 (ig/min.
Tocolysis achieved within (h) Adapt dose to ((.ig/min)
Fig. 1. Schematic representation of the study protocol (Pla 
placebo; Rit =  ritodrine).
Start infusion with 200 |ig/min
i
i - i
1- 1*
14-2
No tocolysis within 2 h: increase to 400 (ig/min 
2 - 2 *
2A-3
3 ~ 3 |
3 |~ 4
No tocolysis within 4 h; increase to 600 jig/min
4 -4 '
50
100
150
200
250
300
350
400
41
5 - 5 $
S j—6
450
500
550
600
tenance treatment (active or placebo) on neonatal 
outcome will be unbiased and similar for both the 
LD and ID schedules (Fig. 1).
A consecutive series of 203 healthy women in
preterm labour, requiring tocolysis with beta- 
mimetics because of three or more regular con­
tractions per 15 min and/or an increase in cervical 50 |ig/min for 12-24 h whereupon oral main- 
dilatation before 34 weeks of gestation, partici- tenance treatment was started. The latter consisted 
pated in this study. After informed consent, of either placebo or sustained release capsules of 
women were allocated at random by numbered, ritodrine (240 mg daily), in a double-blind fashion, 
opaque, sealed envelopes to either one of two for seven days7.
treatment groups. Two additional envelopes were Treatment, whether intravenous or oral, was
drawn erroneously for women who failed to meet stopped in the event of severe side effects, signs of
the entry criterion of labour before 34 weeks and intrauterine infection or fetal distress, and im-
seven for women who had exclusion criteria, such minent delivery. The use of other tocolytic drugs
as earlier tocolytic treatment in the current was not allowed unless clinically indicated because
pregnancy (n =  4) or a diagnosis of intrauterine of failure to respond to ritodrine treatment alone,
infection (n — 1), fetal anomaly (n =  1), or full All other concurrent medication was restricted
dilatation (« =  1) before randomisation. These with the exception of corticosteroid administration
nine women were considered as nonparticipants for fetal lung maturation which was recommended.
prior to any assessment of outcomes. 
Recruitment was stopped when the predeter
The main outcome parameter was successful 
tocolysis defined as the end of intravenous treat-
mined sample size of 200 women was known to ment in the absence of progressive labour or
have been achieved at the five centres. This sample achievement of 34 weeks of gestation, whichever
size has an 80% power of detecting a 20% occurred first. Additional predefined outcomes
difference in the frequency of successful tocolysis were: the total dose of ritodrine administered, the
between the two treatment groups; (a 0-05). duration of intravenous treatment until tapering
Women allocated to the experimental arm (LD; off, infusion rates of ritodrine 12, 24 and 48 h after 
101) received a loading dose of 200 |j,g/min start of treatment, and the number of dose 
ritodrine until tocolysis was reached whereupon adjustments in the first 12, 24 and 48 h of
n
the infusion rate was reduced in a standard fashion 
calculated from the interval between start of the
treatment and tocolysis (Table
treatment.
Assessments of safety and tolerance were made
The conven- on the basis of adverse events, dose adaptations
tional (ID; n =  102) treatment consisted of a dose prompted by side effects, and changes in fetal
of 50 ng/min ritodrine that was increased with heart rate, maternal heart rate and blood pressure
50 |4,g/min about every 15 min until uterine quiesc- between the start of the infusion and the first few
ence was reached or until side effects prohibited hours of treatment. Plasma concentrations of
further dose increases. Both treatments were sodium, potassium, chloride and bicarbonate were
administered with an infusion pump. After cess- measured at the start of treatment and 8 to 16 and
ation of uterine contractions, treatment was 24 to 40 h afterwards.
continued for 24 to 48 h in both groups. Thereafter, Before analysis, all data entry sheets were
the dose was reduced to a maintenance level of assessed by one of us (M.J.N.C.K.), blinded to
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treatment allocation and neonatal outcome. Stat- officially prescribed. We accepted this as normal 
istical analysis was performed in the SAS analysis variation within the confines of clinical practice.
system using Student’s t  test, Wilcoxon two sample 
test and the %2 or Cochran-Mantel-Haenszel x2
Successful tocolysis was defined as arrest of 
intravenous treatment in the absence of progressive
tests. The CIA program was used for confidence labour or at reaching a gestational age of 34
interval analysis
RESULTS
8 weeks. Tocolysis was considered to be only 
partially successful if another agent (always indo- 
methacin) had been co-administered at some stage.
In the five participating centres 212 envelopes were The incidence of successful tocolysis, partial
drawn for the 203 participants and nine non- success and failure were similar in both groups
participants. Two women were excluded from the (Table 3). In eight women treatment was stopped
analysis : one in the LD group because of lost case because of suspected intrauterine
records and one in the ID group because she was ( n 4), abruption (n — 2) or fetal distress (n 2 ),
erroneously started on the loading dose and was rendering an assessment in terms of successful or
5k *therefore withdrawn from the study by her failed tocolysis meaningless (not
obstetrician. Both women gave birth to live infants Table 3).
who survived. The total amount of ritodrine used up to the
The overall evaluation was performed on the start of tapering off did not differ between groups
data of the remaining 201 women of whom 100 had (Table 3). Also the mean infusion rates in jig/min
been allocated to the experimental (LD) schedule at 12, 24 and 48 h after start of treatment were
and 101 to the conventional (ID) schedule. The similar as was the duration of intravenous treat-
groups did not differ statistically in terms of age, ment until the start of maintenance (Table 3).
gestational age, number of twins and triplets, Statistically there was a highly significant diff-
Bishop score9, tocolytic index10, and incidence of erence in the number of dose adjustments in the
ruptured membranes (Table 2). There were 95 first 12, 24 and 48 h of treatment (Cochran-
women (47 %; 50 from the LD group and 45 from Mantel-Haenszel, P <  0-001; Table 3). Side
the ID group; n.s.) who subsequently participated effects (Table 4) precluding further dose increments 
in the double-blind maintenance trial (Fig. 1). or prompting a lowering or even arrest of the 
The loading dose schedule was always admi- infusion occurred significantly more often in the
nistered according to protocol (Table 1), but the ID group (Cochran-Mantel-Haenszel, P 
incremental dose schedule was started with 100 p,g Table 3).
0 *0 2 ;
per min in seven women and in only 30 % of the Starting with the relatively high loading dose 
women (n =  32) was the time interval for dose (200 |j.g/min) in the LD group caused 
augmentations strictly observed at 15 min ; in the complaints and side effects, than the low starting
others the interval was longer at 20 (n 34) or dose of the incremental scheme (50 jig/min) which
even 30 min (n =  30). This was because the had to be upgraded several times. In only one 
participating clinicians were used to being more woman in the ID group was the infusion stopped
cautious with the conventional infusion scheme in the first 12 h because of severe effects
often applying it in a more gradual way than (headache, dizziness, palpitations, tremor, dysp-
Table 2. Characteristics of women participating in the trial.
Loading dose Incremental doseh
Characteristic (n =  100) (n ~  101) P value
; ifTiTIB 11 ^ 1*^0 Û t  irfrTif hît*h■ ■ 11 di 111 »11 mifTÌT*mT~fTTil> 1 hrti 1 il li‘i■ ill II hl
Duration of pregnancy at trial entry 
n <  28 weeks 8 5
n <  32 weeks 51 48
Mean (SD) 217 (15) 219 (15) 0-27**
Prelabour rupture of the membranes 16 14 0-67t
Multiple pregnancy 10 9 0*79f
twin pregnancy 9 8
triplet pregnancy 1 1
Tocolytic index: mean (SD) 3-9 (1-8) 3-7 (1*7) 0-43tt
Bishop score: mean (SD) 4-5 (2-3) 4'8 (1-9) 0*36tt
* Statistical test used: **t  test, tx*  test, t t  Cochran Mantel Haenszel.
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Table 3. Characteristics and main outcomes o f the two treatment schedules.
Loading dose Incremental dose
Characteristic (/} =  100) (« = 1 0 1 )  P value*
Mean infusion rates in jag/min (SEM)
At 12 h 151 (11) 166 (9) 0-08**
At 24 h 152 (11) 154 (8) 0-27**
At 48 h 159 (15) 165 (11) 0-25**
Treatment until tapering off: mean (SEM)
Total dose o f ritodrine (mg) 573 (97) 552 (67) 0-32**
Duration (h) 59 (8) 52 (4) 0-71**
infusion rate adjustments (n)
Within 12 h; mean (SEM) 0-9 (0-08) 2-3 (0-16) < 0-00If
Between 12 and 24 h (SEM) 0-2 (0-06) 0-2 (0-05) 0-7 It
Within 24 h: mean (SEM) 1*1 (0*11) 2-4 (O'20) < 0-00i t
Tocolytic effect 0-911
Success 68 69
Partial success 4 2
Failure 25 25
Not ascertainable 3 5
Women with changes in infusion rate because o f side effects (n) 0-02t
Warranted increase impossible 5 6
Infusion rate reduced 2 9
Infusion stopped 0 1
Delivery
Within 12 h 9 6 0-43tt
Between 12 and 24 h 4 7 0-37tf
Between 24 and 48 h 6 5 0-77tt
<  32 weeks 20 21 0-89tt
32-33 weeks 17 16 0-85tt
34-36 weeks 24 16 0-11 f t
Mean gestational age (days; SEM) 248 (2-7) 250 (2-7) 0-59§
* Statistical test used: **Wilcoxon test, f  Cochran-Mantel-Haenszel, f t x 2 test, § t test.
Table 4. Nature and frequency of maternal side effects in the first 12 h o f  the loading dose and incremental dose schedules.
Moderate or severe Loading dose Incremental dose Difference (%) and
side effects (n =  100) {n =  101) 95% Cl
Any type of side effect 22 32 -9 -6  ( - ■21-7 to 2-5)
Palpitations 8 16 — 7-8 ( —-16*6 to 1-0)
Tachycardia 7 8 -0 -9  ( — 8-1 to 6-3)
Tremor 7 18 —10-7 ( - ■19-6 to — 1 -9)
Agitation 4 3 1-0 ( — 4-0 to 6-0)
Nausea 5 4 1*0 ( — 4-6 to 6-7)
Vomiting 1 4 —• 2*9 ( — 7*2 to 1 *3)
Headache 1 3 —■ 2*0 ( -5*8 to 1-9)
Dyspnea 1 1 0 ( -2 -7  to 2*7)
Total side effects in) 34 57
noea, tachycardia, nausea and agitation) ; she gave 
birth within 4 h of stopping treatment. In 22 other 
women (LD : 7 ; ID : 15) the infusion rate could not 
be increased or had to be lowered because of side 
effects (Table 3).
Changes in serum electrolytes and bicarbonate 
before and 8 to 16 and 24 to 40 h after the start of 
treatment did not differ between the groups. The 
largest change was seen in potassium levels which 
decreased significantly (P < 0*001) from before
treatment in the entire group. Changes in chloride, 
sodium and bicarbonate were not remarkable.
Maternal heart rate and blood pressure were 
recorded more frequently in the ID group than in 
the LD group, because such measurements were 
often linked to adjustments in the infusion rate 
which were more frequent in the ID group. There 
were no statistically significant differences between 
the LD and ID group in maternal heart rate, 
increasing, respectively, by 30 and 27 beats per
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Table 5. Perinatal and neonatal outcome after loading dose and incremental dose treatments,
Outcome
Loading dose
(n 111)
Incremental
(n 111)
Difference (%) and
95% Cl
Fetal and neonatal mortality 1 4 — 2-7 ( — 6*6 to 1 • 1 )
Admission to intensive care 65 60 4-5 ( — 8*5 to 17-5)
Reasons for admission*
Born too early 51 46 4-5 ( — 8*5 to 17-5)
Small for gestational age 15 7 7-2 ( —0-6 to 15-0)
Fetal distress 6 10 — 3*6 ( — 10*4 to 3-2)
Suspected infection 4 5 -0 -9  (-6 -1  to 4-3 )
Sepsis 5 7 — 1-8 ( — 7-8 to 4-1 )
Others 13 18 —■ 4*5 ( —-13-6 to 4*6)
Respiratory distress syndrome 12 17 —4-5 ( — 13*4 to 4-3)
Class I or II 11 14 -2 -7  ( -1 1 -0  to 5-6)
Class >  II 1 3 — 1 '8 ( — 5*3 to 1-7)
Patent ductus arteriosus 1 6 — 4-5 ( — 9' 1 to 0' 1 )
Periventricular-intraventricular haemorrhage 4 15 — 9-9 ( —17-2 to —2-7)
Grade I or II 4 12 -7 -2  ( -1 3 -9  to —0*5)
Grades >  II 0 3 — 2-7 (-—S'? to 0-3)
Hyperbilirubinaemia 32 28 3*6 (-8*1 to 15*3)
* Some infants had several reasons for admission.
min, and in fetal heart rate which increased by bilirubinaemia tended to be more frequent in the
14beats/min in both groups. Changes in or ID group than in the LD group (Table 5). 
absolute levels of systolic blood pressures were not
statistically different between both trial arms. The DISCUSSION
proportion of women with a drop in diastolic As betamimetic agents are potent drugs that can
blood pressure was significantly greater in the ID cause severe adverse effects, it is important to limit
group (LD: 49%; ID: 73 %), but the extent of the the dose and duration of treatment to what is
decrease was similar for both groups. Changes in thought to be clinically useful11. From our previous
pulse pressure in both groups were comparable work we had anticipated that the LD schedule
would result in lower infusion rates and a smallerand of negligible clinical importance.
«
The proportions of women delivering before 32, total amount of ritodrine than the conventional
34 and 37 weeks were similar in both treatment ID schedule recommended by the manufacturer,
groups (Table 3). Including 17 twin and 2 triplet While it is disappointing that this did not
pregnancies each treatment group contains 111 materialize, there is an explanation for it. Being
infants with mean birthweights of 2421+784 g in aware of the potential hazards of ritodrine ad-
the LD group and 2570 +879 g in the ID group. ministration and the fact that side effects are
There was one unexplained intrauterine death at associated nearly as much with changes in infusion
term in the LD group eight weeks after stopping rates as with the rates themselves, clinicians had
ritodrine treatment. Four neonatal deaths oc- become more cautious in their application of the
curred in the ID group (Table 5); two of these conventional infusion schedule4,5. This was shown
were due to immaturity in a twin pregnancy (25 by the fact that clinicians tended to observe longer
between dose increments than the IDweeks), one to cord prolapse and one to hydro-
There were no maternal deaths and no protocol prescribed. While increasing experience
instances of pulmonary oedema. with the new loading dose regimen may have
The main neonatal morbidity was respiratory accentuated this tendency, data were not analysed
distress syndrome which occurred with equal before completion of the trial and there was no
frequency in both treatment groups (Table 5). evidence that the incremental regimen was applied
Periventricular-intraventricular haemorrhage was less conscientiously at the end than at the beginning
less frequent in the LD group (n — 4) than in the of the trial.
ID groups (n = 1 5 ;  Table 5), but a difference in Despite the more cautious approach in applying
this outcome was not a prior hypothesis of our the conventional regimen, the loading dose sched-
outcomes except ad- ule was still tolerated better, particularly duringstudy. All 
mission to neonatal care and hyper- the tmd most crucial first 12 h of treatment.
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On the whole, the incidence of all side effects was incidence20. This does not necessarily exclude,
greater with the ID than with the LD schedule, but though, that our present findings represent a true
the difference was less pronounced than we had instead of a chance difference between the two
anticipated. We should point out that clinicians treatment regimens. If this were so, it would
and pregnant women were not blinded to the constitute a major advantage for the loading dose
treatment schedule and that only the analysis of regimen.
data, but not their registration, occurred without 
knowledge of the treatment group.
As the loading dose scheme is at least equally 
effective as the incremental dose schedule while
As anticipated, tocolysis was reached with far needing fewer dose adjustments and being better
fewer dose adjustments when using the LD rather tolerated in practice, we recommend the loading
than the ID schedule. This may have a beneficial dose schedule as the preferred and safest of the
effect in that each dose adjustment carries a risk of two approaches to tocolytic treatment with rito-
error. This is particularly important when the drine in preterm labour.
adjustment calls for an increase in infusion rate 
and when the clinical staff have relatively 
experience with the use of this powerful agent.
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is less well protected against acute fluctuations in 
blood pressure than the brain of the mature 
infant12. Van de Bor and Walther reported that 
there is only a narrow range of pressure over 
which cerebral blood flow in preterm infants 
remains relatively constant1''®. Thus, fluctuations in 
ritodrine levels to which infants, like their mothers, 
are exposed may be important. Betamimetic- 
induced increases in fetal cardiac output14, 
ticularly when combined with a redistribution to 
the upper body as suggested by Petersen et al 
may lead to significant increases in the perfusion 
pressure to various regions of the brain. While 
several studies found no significant associations 
between betamimetic drug treatment and the
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